FDA Approves Lilly Once-Weekly Insulin
The US Food and Drug Administration approved Eli Lillys once-weekly insulin Onswik for adults with type 2 diabetes. The new treatment offers patients an alternative to daily injections and aims to help control blood sugar levels alongside diet and exercise.
Xurve View
Insights:
Xurve View
ELI LILLY & CO secured United States approval for its once-weekly basal insulin, Onswik, cutting annual patient injections by more than 300. The regulatory greenlight on Thursday expands options for adults managing type 2 diabetes. The treatment enters a competitive market following rival approvals from NOVO NORDISK A/S-B earlier in the year.
